UBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $633.00

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective reduced by equities researchers at UBS Group from $768.00 to $633.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price objective suggests a potential upside of 9.49% from the stock's previous close.

REGN has been the topic of several other reports. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research note on Friday, January 10th. The Goldman Sachs Group reduced their price target on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $941.12.

Regeneron Pharmaceuticals Trading Up 1.6 %

Shares of REGN traded up $9.25 during trading hours on Wednesday, reaching $578.16. 303,649 shares of the company traded hands, compared to its average volume of 734,072. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a market capitalization of $63.21 billion, a price-to-earnings ratio of 15.09, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company's fifty day moving average price is $633.34 and its two-hundred day moving average price is $718.04. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company earned $9.55 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $28,000. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.